Gallium (68Ga) oxodotreotide

（68镓）镓氧奥曲肽

Report date: 2025/11/19 17:58:10
NME

Base Information

Drug NameGallium (68Ga) oxodotreotide
Drug Alias Namedotatate gallium ga-68镓[68Ga]多特安肽Gallium dotatate Ga-68Gallium (68Ga) octreotateGa-68 Dotatate +[10] 
ClassificationDiagnostic agent (In vivo)Radiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Gallium > 68Ga +[5] 
Mechanisms of ActionSomatostatin receptor 2 bindersIonising radiation emittersPositron-emission tomography enhancers
TargetsSomatostatin receptor 2
Therapy Area/Indicationsvon Hippel-Lindau DiseaseProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[10] 
Global Approved IndicationsNeuroendocrine Tumors
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2016/06/01
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAdvanced Accelerator Applications Sa
China Registration ClassN/A

Develop Information

Active CompaniesAaa Usa IncNational Cancer InstituteEmory University +[5] 
Inactive CompaniesUniversity Of Alabama At Birmingham
Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsThyroid Neoplasms +[7] 
Inactive Indicationsvon Hippel-Lindau DiseasePancreatic NeoplasmsCarcinoid Tumor

Other Information

ATC CodeV09
Related LinksDrugBank